The role of costimulatory molecules in T-cell activation.

Renee Jakobsen*

Department of Biomedicine, Aarhus University, Denmark

Introduction

T-cell activation is a tightly regulated process central to adaptive immunity. It is critical for defending the body against pathogens, cancerous cells, and foreign antigens. This process requires more than the simple recognition of antigens via the T-cell receptor (TCR); it also depends heavily on signals from costimulatory molecules. These molecules determine the intensity, quality, and duration of T-cell responses. Without appropriate costimulation, T cells may become anergic (non-responsive) or undergo apoptosis. This article explores the mechanisms by which costimulatory molecules contribute to T-cell activation, their role in immune modulation, and the therapeutic opportunities they offer in immunology [1].

The classical model of T-cell activation involves two critical signals: Antigen recognition through the interaction of the T-cell receptor (TCR) with the antigen–MHC complex on antigen-presenting cells (APCs). Costimulation via specific receptor-ligand interactions, primarily between molecules on the T cell and the APC [2].

The absence of the second signal results in T-cell anergy, highlighting the indispensable role of costimulatory molecules. CD28 is the best-characterized costimulatory receptor on naïve T cells. It binds to CD80 (B7-1) and CD86 (B7-2) on APCs and is crucial for initiating T-cell proliferation, cytokine production (especially IL-2), and survival. This interaction amplifies TCR signaling, lowers the threshold for activation, and supports the generation of memory T cells [3].

Inducible costimulator (ICOS), upregulated upon T-cell activation, binds ICOS ligand (ICOSL) on B cells, dendritic cells, and monocytes. It is important for T follicular helper (Tfh) cell differentiation and B-cell help, particularly in germinal center responses [4].

4-1BB, a member of the tumor necrosis factor receptor superfamily (TNFRSF), is induced upon T-cell activation. Its ligand, 4-1BBL, enhances CD8+ T-cell expansion, survival, and memory formation. This pathway is being actively explored in cancer immunotherapy due to its ability to boost cytotoxic T-cell responses [5].

OX40 and its ligand OX40L promote T-cell proliferation, survival, and cytokine production. They are also involved in maintaining effector and memory T-cell populations. OX40 signaling supports CD4+ T-cell expansion and is being investigated in both cancer and autoimmune therapies [6].

While not a direct T-cell costimulatory interaction, CD40-CD40L (expressed on T cells and APCs, respectively) enhances APC activation and cytokine production. It's vital for "licensing" dendritic cells, thereby strengthening the overall immune response [7].

CTLA-4 competes with CD28 for B7 ligands and sends inhibitory signals to the T cell. The balance between costimulatory and inhibitory signals determines whether a T cell becomes activated, anergic, or regulatory. Costimulatory signals are counterbalanced by coinhibitory molecules such as CTLA-4, PD-1, and LAG-3, which act as immune checkpoints. These molecules downregulate T-cell activity to maintain self-tolerance and prevent tissue damage [8].

Tumors often create immunosuppressive environments by upregulating inhibitory ligands or downregulating costimulatory signals. Enhancing costimulation through agonist antibodies (e.g., anti-CD137 or anti-OX40) is an emerging strategy to boost T-cell function and improve antitumor immunity. In diseases like multiple sclerosis, rheumatoid arthritis, and lupus, inappropriate T-cell activation plays a pathogenic role. Targeting costimulatory pathways with CTLA-4-Ig (abatacept) inhibits CD28 signaling and reduces T-cell activity, offering a therapeutic approach [9].

Blocking costimulatory signals helps prevent graft rejection by promoting T-cell anergy or tolerance. Agents like belatacept, a CTLA-4-Ig fusion protein, are being used to prolong graft survival in organ transplantation. A better understanding of the temporal dynamics and tissue-specific roles of costimulatory molecules will be key to developing next-generation immunotherapies [10].

Conclusion

Costimulatory molecules play an essential role in ensuring effective T-cell activation, immune defense, and long-term immune memory. They serve as crucial molecular switches that can dictate immune outcomes, from tolerance to robust immunity. Understanding and manipulating these pathways has led to significant advances in immunotherapy and transplant medicine, and holds promise for treating a broad range of diseases. As research continues to uncover the complexity of these signaling networks, the potential for targeted and safer immunomodulation will only grow.

References

1. Kretz AL, Trauzold A, Hillenbrand A, et al., TRAILblazing strategies for cancer treatment. Cancers. 2019;11(4):456.

***Correspondence to:** Renee Jakobsen, Department of Biomedicine, Aarhus University, Denmark. E-mail: renee.j@biomed.au.dk

***Received:** 03-Apr-2025, Manuscript No. AAJCIT-25-163913; **Editor assigned:** 04-Apr-2025, Pre QC No. AAJCIT-25-163913(PQ); **Reviewed:** 17-Apr-2025, QC No AAJCIT-25-163913; **Revised:** 21-Apr-2025, Manuscript No. AAJCIT-25-163913(R); **Published:** 28-Apr-2025, DOI:10.35841/aajcit-8.2.258*

***Citation:** Jakobsen R. The role of costimulatory molecules in T-cell activation. J Cancer Immunol Ther. 2025;8(2):258*

2. L Arias J. Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem. 2011;11(1):1-7.
3. Teleanu RI, Chircov C, Grumezescu AM, et al., Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. J Clin Med. 2019;9(1):84.
4. Lee Y, Auh SL, Wang Y, et al., Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Am J Hematol. 2009;114(3):589-95.
5. Slaney CY, Wang P, Darcy PK, et al., CARs versus BiTEs: a comparison between T cell–redirection strategies for cancer treatment. Cancer Discov. 2018;8(8):924-34.
6. Jiang J, Guo W, Liang X. Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. Hum Immunol. 2014;75(11):1128-37.
7. Sethi S, Li Y, H Sarkar F. Regulating miRNA by natural agents as a new strategy for cancer treatment. Curr Drug Targets. 2013;14(10):1167-74.
8. Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159(1):14-26.
9. Teiten MH, Dicato M, Diederich M. Hybrid curcumin compounds: a new strategy for cancer treatment. Mol. 2014;19(12):20839-63.
10. Wu WK, Cho CH, Lee CW, et al., Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 2010;293(1):15-22.

Citation: *Jakobsen R. The role of costimulatory molecules in T-cell activation. J Cancer Immunol Ther. 2025;8(2):258*